Stuart Lye Seeks A$500,000 CAR-T Abroad After Exhausting Myeloma Treatments in New Zealand
Updated
Updated · Bloomberg · Jun 10
Stuart Lye Seeks A$500,000 CAR-T Abroad After Exhausting Myeloma Treatments in New Zealand
1 articles · Updated · Bloomberg · Jun 10
Summary
Stuart Lye, 58, is looking overseas for CAR-T therapy after his high-risk myeloma worsened and he exhausted available treatments in New Zealand.
Three months to live was the prognosis he received in 2018, but chemotherapy, stem cell transplants and drugs extended his life before those options stopped working.
CAR-T is not yet commercially available in New Zealand, and ongoing local trials do not cover his specific cancer, leaving him without a domestic path to the therapy.
A$500,000 is the approximate cost of the treatment in nearby Australia, underscoring why foreign patients are weighing expensive cross-border care as China’s medical tourism market expands.
Is China's cheaper cancer therapy a medical miracle or a high-stakes gamble for desperate patients?
As China offers accessible cures, are Western healthcare systems failing their most critically ill citizens?
"CAR-T Therapy Out of Reach: The Urgent Blood Cancer Crisis for 21,000 New Zealanders"
Overview
In 2025, the relapse of Stuart Lye highlighted a growing crisis for New Zealand blood cancer patients. After exhausting all domestic treatment options, Lye, like many others, was forced to seek life-saving CAR-T therapy overseas, such as in Shanghai. This situation reflects a wider trend of 'medical migration,' where New Zealanders must leave their country because advanced treatments are either unavailable or unfunded at home. The crisis is driven by prolonged waiting times and limited access to new therapies, leaving patients with few choices and underscoring serious gaps in New Zealand’s healthcare system.